Valuation: Hemostemix Inc.

Market Cap 13.74M 9.64M 8.61M 8.03M 7.3M 932M 13.85M 96.54M 37.72M 474M 36.18M 35.4M 1.52B P/E 2024
-4.36x
P/E 2025 -3.12x
Enterprise Value 16.6M 11.64M 10.4M 9.71M 8.82M 1.13B 16.73M 117M 45.57M 573M 43.71M 42.77M 1.84B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
83.37%
Yield 2024 *
-
Yield 2025 -
1 week+8.33%
Current month+8.33%
1 month-13.33%
3 months+44.44%
6 months-7.14%
Current year-27.78%
1 week 0.06
Extreme 0.055
0.06
1 month 0.06
Extreme 0.055
0.08
Current year 0.04
Extreme 0.04
0.11
1 year 0.04
Extreme 0.04
0.12
3 years 0.04
Extreme 0.035
0.42
5 years 0.04
Extreme 0.035
0.42
10 years 0
Extreme 0
5
Manager TitleAgeSince
Chief Executive Officer - 10/02/2020
Director of Finance/CFO - 05/03/2020
Chief Tech/Sci/R&D Officer - 14/10/2021
Director TitleAgeSince
Director/Board Member - 26/11/2019
Director/Board Member 67 09/02/2020
Director/Board Member - 08/04/2020
Date Insider Type Main position Quantity % Market Cap. Importance
30/07/26 Option

Chairman

525,000 0.2654%
22/07/26 Option

Director

385,000 0.1946%
22/07/26 Option

Founder

1,730,000 0.8746%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+8.33%-43.48%-43.48% 9.64M
+4.16%+4.16%+49.37%+94.17% 74.68B
+0.46%-0.97%+23.51%+79.34% 58.7B
+0.17%+0.35%+6.85%+34.55% 48.36B
+0.50%-2.14%+331.33%+702.20% 43.05B
-0.72%-3.99%+28.50%+29.94% 42.48B
+0.34%-0.52%+6.56%+109.35% 41.39B
-0.11%+1.96%+9.19%+52.66% 31.29B
-0.50%-3.10%-10.19%-14.35% 23.93B
-3.32%-10.86%-37.32%+316.28% 22.22B
Average +0.10%-1.13%+36.43%+136.07% 38.61B
Weighted average by Cap. +0.68%-1.56%+52.73%+149.50%

Financials

2024 2025
Net sales - -
Net income -2.62M -1.83M -1.64M -1.53M -1.39M -177M -2.64M -18.38M -7.18M -90.26M -6.89M -6.74M -290M -4.71M -3.31M -2.95M -2.76M -2.5M -320M -4.75M -33.11M -12.94M -163M -12.41M -12.14M -523M
Net Debt 4.23M 2.97M 2.65M 2.47M 2.25M 287M 4.26M 29.72M 11.61M 146M 11.14M 10.9M 469M 2.86M 2.01M 1.79M 1.67M 1.52M 194M 2.88M 20.1M 7.85M 98.7M 7.53M 7.37M 317M
Projected Income Statement - Annual - Hemostemix Inc.
Logo Hemostemix Inc.
Hemostemix Inc. is an autologous stem cell therapy platform company. The Company has developed, patented, and is scaling and selling autologous (patient’s own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01), later neural cell precursors (NCP-01), and cardiomyocyte cell precursors (CCP-01). It holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including ACP-01, CCP-01 and NCP-01. ACP-01 is a clinically relevant and statistically significant treatment for peripheral arterial disease, chronic limb-threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. It has completed a Phase II clinical trial for chronic limb-threatening ischemia. It has two wholly owned subsidiaries, Kwalata Trading Limited and PreCerv Inc. PreCerv Inc. holds a global field of use license to ACP-01 & NCP-01 for the treatment of conditions of the central and peripheral nervous system.
Employees
-
Date Price Change Volume
07/10/26 CA$0.0650 0.00% 7,000
05/10/26 CA$0.0650 +8.33% 21,650
01/10/26 CA$0.0600 0.00% 5,000
30/09/26 CA$0.0600 0.00% 1,100
29/09/26 CA$0.0600 0.00% 1,000